Related references
Note: Only part of the references are listed.Design and discovery of new 1,2,4-triazolo[4,3-c]quinazolines as potential DNA intercalators and topoisomerase II inhibitors
Mohamed S. Alesawy et al.
ARCHIV DER PHARMAZIE (2021)
Design, Synthesis and Biological Evaluation of New HDAC1 and HDAC2 Inhibitors Endowed with Ligustrazine as a Novel Cap Moiety
Mohammad M. Al-Sanea et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2020)
Recent advancements of coumarin-based anticancer agents: An up-to-date review
Tarfah Al-Warhi et al.
BIOORGANIC CHEMISTRY (2020)
Antitumor properties of certain spirooxindoles towards hepatocellular carcinoma endowed with antioxidant activity
Sara T. Al-Rashood et al.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY (2020)
Design, synthesis and anticancer evaluation of thieno[2,3-d]pyrimidine derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers
Souad A. Elmetwally et al.
BIOORGANIC CHEMISTRY (2019)
Design, synthesis, molecular modeling and anti-hyperglycemic evaluation of phthalimide-sulfonylurea hybrids as PPARγ and SUR agonists
Mohamed Ayman El-Zahabi et al.
BIOORGANIC CHEMISTRY (2019)
Design and Discovery of Novel Quinoxaline Derivatives as Dual DNA Intercalators and Topoisomerase II Inhibitors
Ibrahim H. Eissa et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2018)
Design, synthesis and anticancer evaluation of 1H-pyrazolo[3,4-d] pyrimidine derivatives as potent EGFRWT and EGFRT790m inhibitors and apoptosis inducers
Ahmed A. Gaber et al.
BIOORGANIC CHEMISTRY (2018)
Regorafenib: A Review in Metastatic Colorectal Cancer
Sohita Dhillon
DRUGS (2018)
Design, synthesis, molecular modeling and anti-proliferative evaluation of novel quinoxaline derivatives as potential DNA intercalators and topoisomerase II inhibitors
M. K. Ibrahim et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium
Luca Falzone et al.
FRONTIERS IN PHARMACOLOGY (2018)
Cytotoxicity evaluation of a Thai herb using tetrazolium (MTT) and sulforhodamine B (SRB) assays
La-ongthong Vajrabhaya et al.
JOURNAL OF ANALYTICAL SCIENCE AND TECHNOLOGY (2018)
Nintedanib prevented fibrosis progressin and lung cancer growth in idiopathic pulmonary fibrosis
Kentaro Fukunaga et al.
RESPIROLOGY CASE REPORTS (2018)
Novel 4/3-((4-oxo-5-(2-oxoindolin-3-ylidene)thiazolidin-2-ylidene) amino) benzenesulfonamides: Synthesis, carbonic anhydrase inhibitory activity, anticancer activity and molecular modelling studies
Wagdy M. Eldehna et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Thienopyrimidine derivatives exert their anticancer efficacy via apoptosis induction, oxidative stress and mitotic catastrophe
Haneen Amawi et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Cabozantinib for the treatment of kidney cancer
Ahmed Abdelaziz et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2017)
Synthesis, characterization and molecular docking studies of thiouracil derivatives as potent thymidylate synthase inhibitors and potential anticancer agents
Abeer M. El-Naggar et al.
MOLECULAR DIVERSITY (2017)
Synthesis, Characterization and Cytotoxicity of Substituted [1] Benzothieno[3,2-e][1,2,4] triazolo [4,3-a] pyrimidines
Samir Botros et al.
ACTA CHIMICA SLOVENICA (2017)
Design, synthesis, and biological evaluation of thieno[2,3-d]pyrimidine derivatives as novel dual c-Met and VEGFR-2 kinase inhibitors
Jieming Li et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2017)
Medicinal Attributes of Thienopyrimidine Based Scaffold Targeting Tyrosine Kinases and Their Potential Anticancer Activities
Amna Ghith et al.
ARCHIV DER PHARMAZIE (2017)
Design, synthesis, molecular modeling and anti-hyperglycemic evaluation of quinazolin-4(3H)-one derivatives as potential PPARγ and SUR agonists
Mohamed K. Ibrahim et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2017)
Design, synthesis, molecular modeling and biological evaluation of novel 1H-pyrazolo[3,4-b]pyridine derivatives as potential anticancer agents
Ibrahim H. Eissa et al.
BIOORGANIC CHEMISTRY (2016)
Synthesis, Anticancer Activity, Effect on Cell Cycle Profile, and Apoptosis-Inducing Ability of Novel Hexahydrocyclooctathieno[2,3-d]pyrimidine Derivatives
Asmaa Elsayed Kassab et al.
CHEMICAL & PHARMACEUTICAL BULLETIN (2016)
Safety and efficacy profile of lenvatinib in cancer therapy: a systematic review and meta-analysis
Chenjing Zhu et al.
ONCOTARGET (2016)
Discovery of Potent VEGFR-2 Inhibitors based on Furopyrimidine and Thienopyrimidne Scaffolds as Cancer Targeting Agents
Marwa A. Aziz et al.
SCIENTIFIC REPORTS (2016)
Synthesis, antiangiogenesis evaluation and molecular docking studies of 1-aryl-3-[(thieno[3,2-b]pyridin-7-ylthio)phenyl]ureas: Discovery of a new substitution pattern for type II VEGFR-2 Tyr kinase inhibitors
Vera A. Machado et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2015)
Ten things you should know about protein kinases: IUPHAR Review 14
Doriano Fabbro et al.
BRITISH JOURNAL OF PHARMACOLOGY (2015)
Linifanib: current status and future potential in cancer therapy
Caterina Aversa et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2015)
Comparison of in silico tools for evaluating rat oral acute toxicity
R. G. Diaza et al.
SAR AND QSAR IN ENVIRONMENTAL RESEARCH (2015)
Discovery of a Novel Series of Thienopyrimidine as Highly Potent and Selective PI3K Inhibitors
Fangbin Han et al.
ACS MEDICINAL CHEMISTRY LETTERS (2015)
Signal Transduction in Cancer
Richard Sever et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2015)
Prediction of in vivo developmental toxicity of all-trans-retinoic acid based on in vitro toxicity data and in silico physiologically based kinetic modeling
Jochem Louisse et al.
ARCHIVES OF TOXICOLOGY (2015)
Thieno[2,3-d]pyrimidine based derivatives as kinase inhibitors and anticancer agents
Eman Z. Elrazaz et al.
FUTURE JOURNAL OF PHARMACEUTICAL SCIENCES (2015)
Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma-Mechanistics, review of phase III randomized clinical trials, and regulatory implications
Ramez N. Eskander et al.
GYNECOLOGIC ONCOLOGY (2014)
Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial
Ann-Lii Cheng et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Axitinib: A Review of its Safety and Efficacy in the Treatment of Adults with Advanced Renal Cell Carcinoma
Marine Gross-Goupil et al.
CLINICAL MEDICINE INSIGHTS-ONCOLOGY (2013)
VEGF/VEGFR Pathway Inhibitors as Anti-Angiogenic Agents: Present and Future
P. S. Sharma et al.
CURRENT CANCER DRUG TARGETS (2012)
First-Line Treatment of Advanced Breast Cancer With Sunitinib in Combination With Docetaxel Versus Docetaxel Alone: Results of a Prospective, Randomized Phase III Study
Jonas Bergh et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Vascular Endothelial Growth Factor (VEGF) Receptors: Drugs and New Inhibitors
Francesca Musumeci et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Impact of aryloxy-linked quinazolines: A novel series of selective VEGFR-2 receptor tyrosine kinase inhibitors
Antonio Garofalo et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2011)
Synthesis and biological evaluation of substituted (thieno[2,3-d]pyrimidin-4-ylthio)carboxylic acids as inhibitors of human protein kinase CK2
Andriy G. Golub et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2011)
Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes
Thomas Force et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?
Kristy J. Gotink et al.
ANGIOGENESIS (2010)
The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors: A structural analysis of the binding interactions of Gleevec®, Nexavar®, and BIRB-796
Justin Dietrich et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2010)
Pharmacophore modeling and virtual screening studies for new VEGFR-2 kinase inhibitors
Kyungik Lee et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2010)
Design and Synthesis of Tetrahydropyridothieno[2,3-d]pyrimidine Scaffold Based Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors: The Role of Side Chain Chirality and Michael Acceptor Group for Maximal Potency
Chia-Hsien Wu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
SYNTHESIS AND ANTITUMOR ACTIVITY OF SOME NOVEL PYRAZOLE AND THIENOPYRIMIDINE DERIVATIVES
Hala M. Aly
PHOSPHORUS SULFUR AND SILICON AND THE RELATED ELEMENTS (2010)
Vascular Endothelial Growth Factor
Napoleone Ferrara
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2009)
QSAR Studies of CYP2D6 Inhibitor Aryloxypropanolamines Using 2D and 3D Descriptors
Partha Pratim Roy et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2009)
Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
Bernard Escudier et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Pharmacophore modeling studies of type I and type II kinase inhibitors of Tie2
Qing-Qing Xie et al.
JOURNAL OF MOLECULAR GRAPHICS & MODELLING (2009)
Acquired resistance to tyrosine kinase inhibitors during cancer therapy
Jeffrey A. Engelman et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2008)
Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis
Shenhong Wu et al.
LANCET ONCOLOGY (2008)
Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition
Thomas Force et al.
NATURE REVIEWS CANCER (2007)
Inhibiting vascular endothelial growth factor receptor-2 signaling reduces tumor burden in the ApcMin/+ mouse model of early intestinal cancer
R. A. Goodlad et al.
CARCINOGENESIS (2006)
Rational design of inhibitors that bind to inactive kinase conformations
Y Liu et al.
NATURE CHEMICAL BIOLOGY (2006)
Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors
YJ Dai et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Cutaneous side-effects of kinase inhibitors and blocking antibodies
C Robert et al.
LANCET ONCOLOGY (2005)
Design and SAR of thienopyrimidine and thienopyridine inhibitors of VEGFR-2 kinase activity
MJ Munchhof et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2004)
Assessment of the oral rat chronic lowest observed adverse effect level model in TOPKAT, a QSAR software package for toxicity prediction
R Venkatapathy et al.
JOURNAL OF CHEMICAL INFORMATION AND COMPUTER SCIENCES (2004)
Classification of kinase inhibitors using a Bayesian model
XY Xia et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis
S Weis et al.
JOURNAL OF CELL BIOLOGY (2004)
Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor
HK Kim et al.
EUROPEAN JOURNAL OF CANCER (2003)